company background image
VIVIMEDLAB logo

Vivimed Labs NSEI:VIVIMEDLAB Stock Report

Last Price

₹4.95

Market Cap

₹410.4m

7D

0%

1Y

-45.9%

Updated

28 Oct, 2023

Data

Company Financials

Vivimed Labs Limited

NSEI:VIVIMEDLAB Stock Report

Market Cap: ₹410.4m

VIVIMEDLAB Stock Overview

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Vivimed Labs Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivimed Labs
Historical stock prices
Current Share Price₹4.95
52 Week High₹13.95
52 Week Low₹4.85
Beta0.92
1 Month Change0%
3 Month Change-1.00%
1 Year Change-45.90%
3 Year Change-71.71%
5 Year Change-87.79%
Change since IPO-88.68%

Recent News & Updates

Recent updates

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Mar 30
Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Dec 14
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Jun 30
Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Feb 22
Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Jan 19
Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Nov 25
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

Sep 22
Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Jul 31
Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Shareholder Returns

VIVIMEDLABIN PharmaceuticalsIN Market
7D0%0.8%0.5%
1Y-45.9%58.6%44.7%

Return vs Industry: VIVIMEDLAB underperformed the Indian Pharmaceuticals industry which returned 30.3% over the past year.

Return vs Market: VIVIMEDLAB underperformed the Indian Market which returned 19.4% over the past year.

Price Volatility

Is VIVIMEDLAB's price volatile compared to industry and market?
VIVIMEDLAB volatility
VIVIMEDLAB Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.7%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.2%

Stable Share Price: VIVIMEDLAB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VIVIMEDLAB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988607Santosh Varalwarwww.vivimedlabs.com

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates in two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments.

Vivimed Labs Limited Fundamentals Summary

How do Vivimed Labs's earnings and revenue compare to its market cap?
VIVIMEDLAB fundamental statistics
Market cap₹410.42m
Earnings (TTM)-₹3.22b
Revenue (TTM)₹1.73b

0.2x

P/S Ratio

-0.1x

P/E Ratio

Is VIVIMEDLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIVIMEDLAB income statement (TTM)
Revenue₹1.73b
Cost of Revenue₹2.62b
Gross Profit-₹886.40m
Other Expenses₹2.33b
Earnings-₹3.22b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-38.82
Gross Margin-51.14%
Net Profit Margin-185.70%
Debt/Equity Ratio960.3%

How did VIVIMEDLAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.